Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
American Journal of Hypertension
Journal
Overview
Identity
Overview
Publication Venue For
Validation of a Remote Monitoring Blood Pressure Device in Pregnancy.
2023
Association of Cardiovascular Health Metrics With Risk of Transition to Hypertension in Non-Hypertensive Young Adults
. 35:858-866.
2022
Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases
. 35:731-739.
2022
Impact of Asleep and 24-Hour Blood Pressure Data on the Prevalence of Masked Hypertension by Race/Ethnicity
. 35:627-637.
2022
Equity in Hypertension Care and Outcomes: Closing the Black-White Gap in Blood Pressure Control
. 35:500-502.
2022
Predicting Out-of-Office Blood Pressure in a Diverse US Population
. 35:533-542.
2022
Excessive Blood Pressure Response to Clonidine in Hospitalized Patients With Asymptomatic Severe Hypertension
. 35:433-440.
2022
Age-Specific Prevalence and Factors Associated With Normal Blood Pressure Among US Adults
. 35:319-327.
2022
Hypertension Call to Action: Will We Respond to the Call With Action?
. 35:214-216.
2022
Pro-neurotensin/Neuromedin N and Hypertension Risk: A Prospective Study
. 35:281-288.
2022
Factors Associated With Not Having a Healthcare Visit in the Past Year Among US Adults With Hypertension: Data From NHANES 2013–2018
. 35:132-141.
2022
Is Medication Adherence Predictive of Cardiovascular Outcomes and Blood Pressure Control? The Systolic Blood Pressure Intervention Trial (SPRINT)
. 35:182-191.
2022
Circadian Control of Sodium and Blood Pressure Regulation
. 34:1130-1142.
2021
Lifestyle Behaviors Among Adults Recommended for Ambulatory Blood Pressure Monitoring According to the 2017 ACC/AHA Blood Pressure Guideline
. 34:1181-1188.
2021
Decision Tree-Based Classification for Maintaining Normal Blood Pressure throughout Early Adulthood and Middle Age: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) Study
. 34:1037-1041.
2021
Together, we’ve got this: The US surgeon general’s call-to-action on hypertension control
. 34.
2021
Associations between Social Determinants and Hypertension, Stage 2 Hypertension, and Controlled Blood Pressure among Men and Women in the United States
. 34:707-717.
2021
C-Reactive Protein and Incident Hypertension in Black and White Americans in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study
. 34:698-706.
2021
Changes in Hypertension Control in a Community-Based Population of Older Adults, 2011-2013 to 2016-2017
. 34:591-599.
2021
Paradoxical Increase of 24-Hour Urinary Aldosterone Levels in Obese Patients with Resistant Hypertension on a High Salt Diet
. 34:600-608.
2021
Digit Preference in Office Blood Pressure Measurements, United States 2015–2019
. 34:521-530.
2021
N-terminal pro-b-type natriuretic peptide and longitudinal risk of hypertension
. 34:476-483.
2021
The association of orthostatic hypotension with ambulatory blood pressure phenotypes in sprint
. 34:511-520.
2021
Twenty-five-year changes in office and ambulatory blood pressure: Results from the coronary artery risk development in young adults (cardia) study
. 34:494-503.
2021
Blood Pressure in Childhood and Adolescence
. 34:242-249.
2021
Uric Acid Is Not Associated with Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes
. 34:64-72.
2021
Using predicted atherosclerotic cardiovascular disease risk for discrimination of awake or nocturnal hypertension
. 33:1011-1020.
2020
Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study
. 33:949-957.
2020
Factors associated with physician recommendation of home blood pressure monitoring and blood pressure in the US population
. 33:852-859.
2020
Reserpine substantially lowers blood pressure in patients with refractory hypertension: A proof-of-concept study
. 33:741-747.
2020
Uric acid and hypertension: An update with recommendations
. 33:583-594.
2020
Role of inflammatory biomarkers in the prevalence and incidence of hypertension among HIV-positive participants in the START trial
. 33:43-52.
2020
Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group
. 32:1146-1153.
2019
Ethnic differences in nighttime melatonin and nighttime blood pressure: A study in European Americans and African Americans
. 32:968-974.
2019
Health Behaviors, Nocturnal Hypertension, and Non-dipping Blood Pressure: The coronary artery risk development in young adults and jackson Heart study
. 32:759-768.
2019
Blood Pressure Measurement Challenges in Severely Obese Patients
. 32:139-140.
2019
Cardioprotective Effects of Paricalcitol Alone and in Combination with FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies
. 32:34-44.
2019
West African ancestry and nocturnal blood pressure in African Americans: The Jackson Heart Study
. 31:706-714.
2018
Dietary sodium modifies serum uric acid concentrations in humans
. 30:1196-1202.
2017
11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension
. 30:518-523.
2017
Cumulative exposure to systolic blood pressure during young adulthood through midlife and the urine albumin-to-creatinine ratio at midlife
. 30:502-509.
2017
Psychosocial Correlates of Nocturnal Blood Pressure Dipping in African Americans: The Jackson Heart Study
. 29:904-912.
2016
Potential Errors and Omissions Related to the Analysis and Conclusions Reported in Cuspidi C, et al., AJH 2014; 27(2):146-156
. 29:780-781.
2016
Prehypertension Is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study
. 29:568-574.
2016
Clock genes explain a large proportion of phenotypic variance in systolic blood pressure and this control is not modified by environmental temperature
. 29:132-140.
2016
Is isolated nocturnal hypertension a reproducible phenotype?
. 29:33-38.
2016
Nocturnal blood pressure in young adults and cognitive function in midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) study
. 28:1240-1247.
2015
Is pulse pressure an independent risk factor for incident stroke, REasons for geographic and racial differences in stroke
. 28:987-994.
2015
Systolic blood pressure control among individuals with type 2 diabetes: A comparative effectiveness analysis of three interventions
. 28:995-1009.
2015
Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the coronary artery risk development in young adults (CARDIA) study
. 28:640-648.
2015
Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats
. 27:720-726.
2014
Prehypertension and incident acute coronary heart disease in the reasons for geographic and racial differences in stroke (Regards) study
. 27:245-251.
2014
Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: Challenges and lessons learned
. 27:1052-1060.
2014
Blood pressure after recent stroke: Baseline findings from the secondary prevention of small subcortical strok
. 26:1114-1122.
2013
Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease
. 25:789-796.
2012
Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension
. 24:708-715.
2011
Moderate waist circumference and hypertension prevalence: The REGARDS study
. 24:482-488.
2011
Prehypertension, racial prevalence and its association with risk factors: Analysis of the reasons for geographic and racial differences in stroke (REGARDS) study
. 24:194-199.
2011
Adjusting adiposity and body weight measurements for height alters the relationship with blood pressure in children
. 23:904-910.
2010
The association of cell cycle checkpoint 2 variants and kidney function: Findings of the family blood pressure program and the atherosclerosis risk in communities study
. 22:552-558.
2009
Prenatal programming: Maybe not so hopeless after all?
. 22:348.
2009
Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension
. 18:805-812.
2005
A summary of the effects of antihypertensive medications on measured blood pressure
. 18:935-942.
2005
A unifying pathway for essential hypertension
. 18:431-440.
2005
Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals
. 18:287-294.
2005
Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study
. 17:839-844.
2004
Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process
. 17:S23-S30.
2004
Genome scan for hypertension in nonobese African Americans: The National Heart, Lung, and Blood Institute Family Blood Pressure Program
. 17:834-838.
2004
A genome-wide linkage analysis investigating the determinants of blood pressure in whites and African Americans.
. 16:151-153.
2003
Excess dietary glucose alters renal function before increasing arterial pressure and inducing insulin resistance
. 15:773-779.
2002
Are there meaningful differences in blood pressure control with current antihypertensive agents?
. 15:14S-21S.
2002
Obesity: Its time has come
. 15:655-656.
2002
Urinary excretion of vasoactive factors are correlated to sodium excretion
. 14:1003-1006.
2001
Elevated potassium intake inhibits neointimal proliferation in the swine coronary artery
. 14:879-886.
2001
Cardiovascular effects of estrogen.
. 14:186S-193S.
2001
The role of the central nervous system in NaCl-sensitive hypertension in spontaneously hypertensive rats.
. 14:155S-162S.
2001
Factors affecting blood pressure responses to diet: The vanguard study
. 13:956-965.
2000
High potassium intake inhibits neointima formation in the rat carotid artery balloon injury model
. 13:1014-1020.
2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life study
. 13:899-906.
2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
. 13:899-906.
2000
Insulin and hypertension in the NHLBI family heart study
. 13:240-250.
2000
Newly emerging pharmacologic differences in angiotensin II receptor blockers
. 13.
2000
Newly emerging pharmacologic differences in angiotensin II receptor blockers.
. 13:18S-24S.
2000
Treating multiple-risk hypertensive populations.
. 12:121S-129S.
1999
Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises
. 12:653-664.
1999
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
. 12:414-417.
1999
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
. 12:414-417.
1999
Management of the hypertensive patient with coronary artery disease.
. 12:56S-62S.
1999
Management of the hypertensive patient with coronary artery disease
. 12:56S-62S.
1999
Treating multiple-risk hypertensive populations
. 12:121-129.
1999
The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study.
. 11:192S-194S.
1998
Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
. 11:88S-94S.
1998
Case study
. 11.
1998
Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension
. 11:31-40.
1998
Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension.
. 11:31-40.
1998
Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension
. 11:88S-94S.
1998
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
. 10:735-742.
1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
. 10:705-713.
1997
ALLHAT and calcium channel blockers [3]
. 10:142-143.
1997
ALLHAT and calcium channel blockers. ALLHAT Research Group.
. 10:142-143.
1997
Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients
. 10:68-76.
1997
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension
. 10:735-742.
1997
Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742))
. 10:1081.
1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods
. 10:705-713.
1997
Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the coronary artery risk development in young adults (CARDIA) study
. 9:915-923.
1996
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
. 9:342-360.
1996
Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
. 9:342-360.
1996
Pressor and bradykardie effects of centrally administered relaxin in conscious rats
. 8:375-381.
1995
Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats.
. 5:210-218.
1992
Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive rats
. 5:210-218.
1992
Ganglion atrial natriuretic peptide in nacl sensitive spontaneously hypertensive rats
. 5:806-810.
1992
The calcium antagonists in the 1990s. An overview.
. 4:396S-405S.
1991
Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats.
. 4:449-455.
1991
Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive rats
. 4:449-455.
1991
Diagnosis of renovascular hypertension after renal transplantation
. 4:724S-730S.
1991
Report of the working party group on determining the radionuclide of choice
. 4:747S-748S.
1991
The calcium antagonists in the 1990s an overview
. 4:396S-405S.
1991
Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism.
. 3:179S-188S.
1990
Dietary ca
2+
prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism
. 3:179S-188S.
1990
Central mechanisms of hypertension.
. 2:477-485.
1989
Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats.
. 2:435-439.
1989
Central mechanisms of hypertension
. 2:477-485.
1989
Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats
. 2:435-439.
1989
The use of transcutaneous clonidine hydrochloride in the patient with diabetes mellitus and mild hypertension.
. 1:315-321.
1985
Identity
International Standard Serial Number (issn)
0748-450X
0895-7061
Electronic International Standard Serial Number (eissn)
1941-7225